GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » Ending Cash Position

SHJBF (Shanghai Junshi Biosciences Co) Ending Cash Position : $373.75 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Ending Cash Position?

Shanghai Junshi Biosciences Co's Ending Cash Position for the quarter that ended in Jun. 2024 was $373.75 Mil.

Shanghai Junshi Biosciences Co's quarterly Ending Cash Position increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($631.73 Mil) but then declined from Mar. 2024 ($631.73 Mil) to Jun. 2024 ($373.75 Mil).

Shanghai Junshi Biosciences Co's annual Ending Cash Position increased from Dec. 2021 ($550.23 Mil) to Dec. 2022 ($860.18 Mil) but then declined from Dec. 2022 ($860.18 Mil) to Dec. 2023 ($529.14 Mil).

Shanghai Junshi Biosciences Co Ending Cash Position Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Ending Cash Position Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 173.09 517.64 550.23 860.18 529.14

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 677.77 - 631.73 373.75 349.68

Shanghai Junshi Biosciences Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Junshi Biosciences Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=839.884+-310.747
=529.14

Shanghai Junshi Biosciences Co's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=559.183+-185.43
=373.75

Shanghai Junshi Biosciences Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » Ending Cash Position
Comparable Companies
HKSE:01548 HKSE:01530 HKSE:09969 HKSE:01952 HKSE:09995 HKSE:06855 HKSE:06826 HKSE:02696 HKSE:02410 HKSE:02162 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
01877:Hong Kong 8SJ:Germany 688180:China
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Website
https://www.junshipharma.com
Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.